Solid Tumors Clinical Trials in New York, New York

20 studies are recruiting for solid tumors in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York, New York

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

   A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   22 in total

   Run by

   Incyte Corporation

   See if you can join NCT07195916 on ClinicalTrials.gov

4. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US031, New York, New York

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

5. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

   The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health Perlmutter Cancer Center, New York, New York

   Locations

   42 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT05315700 on ClinicalTrials.gov

6. First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

   This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   7 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06644755 on ClinicalTrials.gov

7. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

   The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, New York, New York

   Locations

   25 in total

   Run by

   Arcus Biosciences, Inc.

   See if you can join NCT05536141 on ClinicalTrials.gov

8. A Study of ZL-1310 in Participants With Selected Solid Tumors

   A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center, New York, New York

   Locations

   23 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT06885281 on ClinicalTrials.gov

9. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

10. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

    Stage

    Phase 2

    Ages

    8 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Locations

    70 in total

    Run by

    Fore Biotherapeutics

    See if you can join NCT05503797 on ClinicalTrials.gov

11. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center, New York, New York

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

12. Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

    The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Zai Lab Site 02002, New York, New York

    Locations

    8 in total

    Run by

    Zai Lab (Shanghai) Co., Ltd.

    See if you can join NCT07374848 on ClinicalTrials.gov

13. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    34 in total

    Run by

    Incyte Corporation

    See if you can join NCT06179160 on ClinicalTrials.gov

14. Genomic Profiling in Cancer Patients

    The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. So…

    Stage

    Not phased

    Ages

    Any age

    Site

    Metropolitan Hospital Center, New York, New York

    Locations

    18 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT01775072 on ClinicalTrials.gov

15. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

    The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

    Stage

    Phase 1

    Ages

    18 and older

    Site

    GSK Investigational Site, New York, New York

    Locations

    65 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06431594 on ClinicalTrials.gov

16. DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

    A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

    Stage

    Phase 2

    Ages

    18 and older

    Site

    USA04-0, New York, New York

    Locations

    37 in total

    Run by

    DualityBio Inc.

    See if you can join NCT06953089 on ClinicalTrials.gov

17. QTX3034 in Patients With KRAS G12D Mutation

    Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    14 in total

    Run by

    Quanta Therapeutics

    See if you can join NCT06227377 on ClinicalTrials.gov

18. ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

    The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    4 in total

    Run by

    ORIC Pharmaceuticals

    See if you can join NCT06816992 on ClinicalTrials.gov

19. The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

    The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studi…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Rockefeller Outpatient Pavilion (53rd Street), New York, New York

    Locations

    67 in total

    Run by

    Pfizer

    See if you can join NCT05203172 on ClinicalTrials.gov

20. Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

    The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Montefiore Cancer Center, New York, New York

    Locations

    9 in total

    Run by

    Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

    See if you can join NCT06963281 on ClinicalTrials.gov